BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 29329782)

  • 1. LPA-induced migration of ovarian cancer cells requires activation of ERM proteins via LPA
    Park J; Jang JH; Oh S; Kim M; Shin C; Jeong M; Heo K; Park JB; Kim SR; Oh YS
    Cell Signal; 2018 Apr; 44():138-147. PubMed ID: 29329782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells.
    Kim EK; Park JM; Lim S; Choi JW; Kim HS; Seok H; Seo JK; Oh K; Lee DS; Kim KT; Ryu SH; Suh PG
    J Biol Chem; 2011 Jul; 286(27):24036-45. PubMed ID: 21602274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells.
    Chen M; Towers LN; O'Connor KL
    Am J Physiol Cell Physiol; 2007 May; 292(5):C1927-33. PubMed ID: 17496233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.
    Yu S; Murph MM; Lu Y; Liu S; Hall HS; Liu J; Stephens C; Fang X; Mills GB
    J Natl Cancer Inst; 2008 Nov; 100(22):1630-42. PubMed ID: 19001604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential involvement of ezrin/radixin/moesin proteins in sphingosine 1-phosphate-induced human pulmonary endothelial cell barrier enhancement.
    Adyshev DM; Moldobaeva NK; Elangovan VR; Garcia JG; Dudek SM
    Cell Signal; 2011 Dec; 23(12):2086-96. PubMed ID: 21864676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osmotic cell shrinkage activates ezrin/radixin/moesin (ERM) proteins: activation mechanisms and physiological implications.
    Rasmussen M; Alexander RT; Darborg BV; Møbjerg N; Hoffmann EK; Kapus A; Pedersen SF
    Am J Physiol Cell Physiol; 2008 Jan; 294(1):C197-212. PubMed ID: 17977945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential targeting of lysophosphatidic acid LPA
    Olianas MC; Dedoni S; Onali P
    Eur J Pharmacol; 2023 Nov; 959():176064. PubMed ID: 37758013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
    Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
    Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LPA3 is a precise therapeutic target and potential biomarker for ovarian cancer.
    Zhao P; Yun Q; Li A; Li R; Yan Y; Wang Y; Sun H; Damirin A
    Med Oncol; 2022 Jan; 39(2):17. PubMed ID: 34982278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LPA2 receptor mediates mitogenic signals in human colon cancer cells.
    Yun CC; Sun H; Wang D; Rusovici R; Castleberry A; Hall RA; Shim H
    Am J Physiol Cell Physiol; 2005 Jul; 289(1):C2-11. PubMed ID: 15728708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The G12/13-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration.
    Bian D; Mahanivong C; Yu J; Frisch SM; Pan ZK; Ye RD; Huang S
    Oncogene; 2006 Apr; 25(15):2234-44. PubMed ID: 16301993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
    Yu X; Zhang Y; Chen H
    BMC Cancer; 2016 Nov; 16(1):846. PubMed ID: 27809800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysophosphatidic acid stimulates activation of focal adhesion kinase and paxillin and promotes cell motility, via LPA1-3, in human pancreatic cancer.
    Liao Y; Mu G; Zhang L; Zhou W; Zhang J; Yu H
    Dig Dis Sci; 2013 Dec; 58(12):3524-33. PubMed ID: 24061591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAFTK/Pyk2 mediates LPA-induced PC12 cell migration.
    Park SY; Schinkmann KA; Avraham S
    Cell Signal; 2006 Jul; 18(7):1063-71. PubMed ID: 16199135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular smooth muscle migration and proliferation in response to lysophosphatidic acid (LPA) is mediated by LPA receptors coupling to Gq.
    Kim J; Keys JR; Eckhart AD
    Cell Signal; 2006 Oct; 18(10):1695-701. PubMed ID: 16504475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingosine 1-phosphate-mediated activation of ezrin-radixin-moesin proteins contributes to cytoskeletal remodeling and changes of membrane properties in epithelial otic vesicle progenitors.
    Cencetti F; Bernacchioni C; Bruno M; Squecco R; Idrizaj E; Berbeglia M; Bruni P; Donati C
    Biochim Biophys Acta Mol Cell Res; 2019 Apr; 1866(4):554-565. PubMed ID: 30611767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites.
    Komachi M; Tomura H; Malchinkhuu E; Tobo M; Mogi C; Yamada T; Kimura T; Kuwabara A; Ohta H; Im DS; Kurose H; Takeyoshi I; Sato K; Okajima F
    Carcinogenesis; 2009 Mar; 30(3):457-65. PubMed ID: 19129242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells.
    Jeong KJ; Park SY; Seo JH; Lee KB; Choi WS; Han JW; Kang JK; Park CG; Kim YK; Lee HY
    Exp Mol Med; 2008 Dec; 40(6):607-16. PubMed ID: 19116446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer.
    Shida D; Watanabe T; Aoki J; Hama K; Kitayama J; Sonoda H; Kishi Y; Yamaguchi H; Sasaki S; Sako A; Konishi T; Arai H; Nagawa H
    Lab Invest; 2004 Oct; 84(10):1352-62. PubMed ID: 15220934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noise-induced cochlear F-actin depolymerization is mediated via ROCK2/p-ERM signaling.
    Han Y; Wang X; Chen J; Sha SH
    J Neurochem; 2015 Jun; 133(5):617-28. PubMed ID: 25683353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.